Nanotechnology-based delivery of CRISPR/Cas9 for cancer treatment

[Display omitted] CRISPR/Cas9 (Clustered Regularly Interspaced Short Palindromic Repeats-associated protein 9) is a potent technology for gene-editing. Owing to its high specificity and efficiency, CRISPR/Cas9 is extensity used for human diseases treatment, especially for cancer, which involves mult...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Advanced drug delivery reviews Jg. 176; S. 113891
Hauptverfasser: Xu, Xiaoyu, Liu, Chang, Wang, Yonghui, Koivisto, Oliver, Zhou, Junnian, Shu, Yilai, Zhang, Hongbo
Format: Journal Article
Sprache:Englisch
Veröffentlicht: Netherlands Elsevier B.V 01.09.2021
Schlagworte:
Animals
Cancer treatment
Clinic application
CRISPR-Cas Systems
CRISPR/Cas9
Delivery vectors
Gene Editing
Humans
Nanotechnology
Nanotechnology - methods
Neoplasms - genetics
Neoplasms - therapy
CRISPR/Cas9
Delivery vectors
Cancer treatment
Gene editing
Nanotechnology
Clinic application
ISSN:0169-409X, 1872-8294, 1872-8294
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:[Display omitted] CRISPR/Cas9 (Clustered Regularly Interspaced Short Palindromic Repeats-associated protein 9) is a potent technology for gene-editing. Owing to its high specificity and efficiency, CRISPR/Cas9 is extensity used for human diseases treatment, especially for cancer, which involves multiple genetic alterations. Different concepts of cancer treatment by CRISPR/Cas9 are established. However, significant challenges remain for its clinical applications. The greatest challenge for CRISPR/Cas9 therapy is how to safely and efficiently deliver it to target sites in vivo. Nanotechnology has greatly contributed to cancer drug delivery. Here, we present the action mechanisms of CRISPR/Cas9, its application in cancer therapy and especially focus on the nanotechnology-based delivery of CRISPR/Cas9 for cancer gene editing and immunotherapy to pave the way for its clinical translation. We detail the difficult barriers for CRISIR/Cas9 delivery in vivo and discuss the relative solutions for encapsulation, target delivery, controlled release, cellular internalization, and endosomal escape.
Bibliographie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
ISSN:0169-409X
1872-8294
1872-8294
DOI:10.1016/j.addr.2021.113891